Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients-Reference-Cited by-同舟云学术

Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients

Published:2019-10-28 Issue:21 Volume:3 Page:3196-3200
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Maffioli Margherita¹^ORCID,Giorgino Toni²³^ORCID,Mora Barbara¹,Iurlo Alessandra⁴^ORCID,Elli Elena⁵^ORCID,Finazzi Maria Chiara⁶,Caramella Marianna⁷,Rumi Elisa⁸^ORCID,Carraro Maria Cristina⁹,Polverelli Nicola¹⁰^ORCID,D’Adda Mariella¹¹,Malato Simona¹²,Rossi Marianna¹³,Molteni Alfredo¹⁴^ORCID,Vismara Alessandro¹⁵,Sissa Cinzia¹⁶,Spina Francesco¹⁷,Anghilieri Michela¹⁸,Cattaneo Daniele⁴,Renso Rossella⁵,Bellini Marta⁶,Pioltelli Maria Luisa⁷,Cavalloni Chiara⁸,Barraco Daniela¹,Accetta Raffaella¹⁹,Bertù Lorenza²⁰,Della Porta Matteo Giovanni¹³,Passamonti Francesco²⁰

Affiliation:

1. Hematology Unit, Ospedale di Circolo, ASST Sette Laghi, Varese, Italy;

2. Biophysics Institute (IBF-CNR), National Research Council of Italy, Milan, Italy;

3. Department of Biosciences, University of Milan, Milan, Italy;

4. Hematology Division, Foundation Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy;

5. Hematology Division and Bone Marrow Unit, Ospedale San Gerardo, Monza, Italy;

6. Department of Hematology, ASST Papa Giovanni XXIII, Bergamo, Italy;

7. Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy;

8. Department of Molecular Medicine, University of Pavia, Pavia, Italy;

9. Hematology and Transfusional Medicine Unit, ASST Fatebenefratelli Sacco, Milan, Italy;

10. Unit of Blood Diseases and Stem Cell Transplantation, ASST Spedali Civili di Brescia, Brescia, Italy;

11. Department of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy;

12. Hematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, Milan, Italy;

13. Department of Hematology, Cancer Center, IRCCS Humanitas Research Hospital/Humanitas University, Rozzano, Italy;

14. Hematology Unit, ASST Cremona, Cremona, Italy;

15. Onco-Hematology Unit, ASST-Rhodense, Rho, Italy;

16. Department of Hematology and Transfusion Medicine, ASST Mantova, Mantova, Italy;

17. Hematology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy;

18. Oncology Department, ASST Lecco, Lecco, Italy;

19. Cytogenetics and Genetics Laboratory, Ospedale di Circolo, ASST Sette Laghi, Varese, Italy; and

20. Department of Medicine and Surgery, University of Insubria, ASST Sette Laghi–Ospedale di Circolo, Varese, Italy

Abstract

Key PointsWe present real-world data on all ruxolitinib-treated myelofibrosis patients in a 10-million-resident region, with a follow-up of 2 years. We found no evidence of an increased risk of developing lymphomas.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/3/21/3196/1505832/advancesadv2019000646.pdf

Reference18 articles.

1. Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients;Rumi;Haematologica,2011

2. Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study;Frederiksen;Blood,2011

3. Risk of second cancers in chronic myeloproliferative neoplasms;Susini;Blood,2012

4. Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study;Barbui;Leukemia,2019

5. A population-based analysis of second malignancies among patients with myeloproliferative neoplasms in the SEER database;Brunner;Leuk Lymphoma,2016

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Contemporary Challenges in Polycythemia Vera Management From the Perspective of Patients and Physicians;Clinical Lymphoma Myeloma and Leukemia;2024-08

2. Biologics Versus JAK Inhibitors. Part I: Cancer Risk. A Narrative Review;Dermatology and Therapy;2024-05-19

3. Does Double Mean Trouble? Coexistence of Myeloproliferative and Lymphoproliferative Neoplasms;Journal of Clinical Medicine;2024-03-21

4. Using real-world evidence in haematology;Best Practice & Research Clinical Haematology;2024-03

5. Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib;Blood;2024-01-11